"Old Qi, sit down." Shen Qi poured a glass of water for Director Qi.

"That's right, your chemical project c01b, which is a benzoazacea compound mentioned in the paper published on JACS. A pharmaceutical company wants to buy your patent." Director Qi is indeed the God of Wealth in the center. He said again: "Pharmaceutical companies may not dare to look for someone as big as you, so they found me."

"No problem, we can transfer the patent of c01b. Who is the buyer?" Shen Qi asked.

Director Qi said: "The buyer is Green Mountain Pharmaceutical, a subsidiary established by Pfizer in China and a US-owned enterprise."

Shen Qi said "Oh": "Pfizer's subsidiary is interesting."

Director Qi, who is proficient in legal and commercial operations, said: "I roughly understand some situations. Your c01b is said to be similar to the smoking cessation drug Jibishi launched by Pfizer in 1997. The administrative protection of Jibishi in my country has expired, which means that the patent of this smoking cessation drug has expired. When I was studying in the United States, I specially studied Pfizer's operating cases. In the past 20 years, Pfizer has invested a lot of manpower, material resources and financial resources to acquire it."

The current situation of chemical drugs in China is that once the patents of the marketed patented drugs expire, a large number of generic drugs will emerge. The result is that generic drugs occupy more than 90% of the Chinese chemical drug market.

There are advantages and disadvantages. Generic drugs with imitation and effects almost the same as original drugs are cheaper and can afford them.

However, from the long-term development of China's pharmaceutical industry, the disadvantages outweigh the benefits.

Most Chinese pharmaceutical companies blindly imitate it, resulting in very weak core R&D capabilities and almost losing their innovation capabilities.

The pharmaceutical industry is a technology-led industry. Pharmaceutical companies without technological innovation will not be able to become bigger and stronger, and may even survive.

If there are too many generic drugs of the same type, pharmaceutical companies will start to fight price wars.

Many small and medium-sized pharmaceutical companies in China specialize in producing generic drugs. In the fierce competition and even chaotic price war, most small and medium-sized pharmaceutical companies have lost money all year round, and go bankrupt after losses, or are acquired by large pharmaceutical groups.

Another big market for generic drugs is India. There is a pharmaceutical company in India that specializes in imitating Pfizer's patented drugs. The quality of the imitation drugs is quite high, so high that even FDA has recognized it.

This Indian pharmaceutical company has copied more than 100 patented Pfizer drugs, of which 39 generic drugs have obtained operating rights in the US market.

The United States advocates global trade, fair competition, and opposes monopoly. At least the US government is fair and just in response to Indian companies.

The drug patent expires and people have the right to copy it, and Pfizer cannot sue it.

In the case studied by Director Qi, Pfizer changed its operating model. Since it could not crack down on counterfeit factories, Pfizer acquired the Indian pharmaceutical company aurobindo, which has been committed to imitating them all his life.

At the same time, Pfizer's wholly-owned subsidiary Greenstone Pharmaceutical has purchased a large number of generic drugs after the patent expires worldwide.

The current operating model of the wealthy pharmaceutical giant Pfizer is to maintain the core competitiveness of independently developing new drugs, and simultaneously acquire generic drug companies and generic drugs.

The business of Pfizer's subsidiary, Greenshan Pharmaceutical, is similar to that of Greenstone, which they set up in the United States, is just three words: Buy Buy Buy.

Shen Qi said: "So in Pfizer's opinion, our c01b imitates their rings and will definitely fit?"

Director Qi explained: "The patent bill for drugs is very complicated and difficult to describe. Simply put, the same drug can also apply for different patents due to different preparation methods, which is a patent in terms of technology and technology."

Shen Qi has also learned the rules of the game in the pharmaceutical industry during this period. There is a senior person in his family who is his doctor's mother.

Starting from the mid-20th century, the development of chemical drugs has made rapid progress due to the development of chemical science. Some new compounds were quickly identified in the laboratory and applied to clinical research.

After decades of development, the research and development of chemical drugs is becoming more and more complex and long. The disciplines involved are not only chemistry, but also require knowledge of biology, medicine, information science (computer-assisted), materials science and other knowledge.

Currently, it takes an average of 12 years for a new drug to go public from its initial laboratory research to its launch.

According to statistics from the World Health Organization, only 5 of the 5,000 compounds conducted preclinical trials can enter subsequent clinical trials.

Only one of the compounds can be finally approved and marketed.

A complete new compound research and development cycle is more than 10 years, and the average cost is billions of dollars. International pharmaceutical giants or large cross companies target a single compound research team. It is normal for more than 100 professionals to test the team, and the process involved is extremely complicated and complicated.

Shen Qi can only do the stage of synthesising samples in the laboratory and animal experiments. His center does not have the conditions to complete the full set of drug research and development, testing, and improvement: "I decided to sell the patent for c01b."

Director Qi reminded: "The Americans' bids will not be too high."

Shen Qi nodded and said, "Understand, my c01b has not done any experiments, even animal experiments. Since Green Mountain Pharmaceutical dares to buy, I dare to sell them."

Compounds that conduct preclinical tests can enter the clinical stage i test whether the compounds have toxicity or other dangerous side effects on normal and healthy people. This promotion rate is only one in a thousand.

There are ii~iv after clinical stage i, and the uncertainty is too high.

Shen Qi and Lao Yan had a mistake in synthesizing c01b, let alone clinical practice, have never even done animal experiments.

Whether c01b has actual value will take many years to determine.

Some people dare to buy laboratory compounds c01b at this stage, which requires strong predictive power and also has gambling luck.

Drug research and development is a dramatic industry.

The new drug research and development team of Ragan Company in the United States successfully synthesized a new compound sevoflurane in experiments in 1968. They observed that the sevoflurane decomposition product had certain nephrotoxicity in the 210 degrees Celsius high temperature test.

Therefore, American R&D personnel believed that sevoflurane had no future and sold its patent to Japan's Marushi Company at an extremely low price.

Marushi Company was secretly happy, and they felt like they had a treasure.

After optimization and improvement, Marushi Company launched an improved version of sevoflurane in 1993, which was first launched in japan under the trade name ultane.

In nearly 2 million clinical observations, sevoflurane showed excellent efficacy and safety, and it was subsequently sold in dozens of countries including China, the United States, South Korea, etc.

The Chinese product name of sevoflurane is Kateli, which is an inhalation general anesthetic. Many hospitals in China use Kateli when performing surgery on patients.

In the eyes of American researchers, compounds that have no future have become babies in the hands of japan pharmacists. This is the drama of the drug development industry.

Of course, the cycle of turning waste into treasure is quite long. It took Marushi Company a full 25 years to make sevoflurane a recognized excellent anesthetic in the medical community.

Not to mention 25 years, Shen Qi didn't even want to wait for 5 years. His purpose in entering the chemical industry was not to develop smoking cessation drugs. C01b was just an unexpected gain: "Then please Director Qi, I mean that C01b can be sold. Director Qi will negotiate with the other party in accordance with the industry rules."

In line with the old saying, mathematics and physics are fires that point out the road, and chemical biology is a crematorium and a pit for burying science students.

Shen Qi lit the fire and lit the light.

Now Shen Qi has fallen into the trap, this is the fate of science students.

Playing with biochemistry is really a very complicated project. Shen Qi’s most convenient way is mathematics, physics and politics.

Because of Director Qi's temporary visit, Shen Qi only wrote an extra article about condensed matter physics before getting off work at 5 o'clock.

"I'll work overtime today and go home before 10 o'clock." Shen Qi sent a message to Ou Ye, and he wanted to complete the other two extra physics chapters in one go.

There are four extras in mathematics and physics. If all of them are published, Shen Qi predicts that he can save points for maths who can reach level 15 in 15.

Ou Ye replied to the message: "Go home to have dinner first, and then work overtime after eating."

Academician Shen’s villa is very close to Yanda and is only a ten-minute walk.

The wife of heaven and earth is the biggest. When her wife ordered her to go home for dinner, she had to go home for dinner.

Shen Qi went home for dinner. After dinner, he teased the kids and even added a ghost shift. He didn't want to work overtime anymore.

The next day, Shen Qi finished all the extra chapters and sent them to relevant mathematical and physics journals, and then reviewed the documents that needed him to confirm.

The reason why a leader of a scientific research institution or research team is called a boss is because the bosses are busy with business and there are many documents that the boss needs to deal with.

Especially if he is a benign boss, his signature may involve tens of millions or even billions of scientific research funds.

Scientific researchers with the title of associate professor at the center or above are eligible to apply for scientific research projects separately.

After receiving training as the president of the Party School, Shen Qi was very cautious about applying for large amounts of scientific research funds.

It doesn’t matter if the project below 1 million yuan is not important, Shen Qi approved it casually.

Shen Qi must strictly control theoretical research projects with more than 1 million and application projects with more than 10 million.

Associate Professor Xiao Junlong applied for a math project, with the application fund of 986,327 yuan, and the list was zero and complete. The details of the list were clear.

"Card valve, right? Lao Xiao, you have studied me thoroughly." Shen Qi's hand holding the pen did not sign for a long time. All the people under him became energetic.
Chapter completed!